Increasing number of product approvals by regulatory authorities for the treatment of cancer is expected to drive growth of the subcutaneous drug delivery market. For instance, in February 2019, ...

This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...

In this exclusive MedPage Today video, Jorge Nieva, MD, of the Keck School of Medicine at the University of Southern California in Los Angeles, discusses the growing trend of subcutaneous formulations ...

In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in-class infused drug quickly became the best-selling treatment in a crowded multiple sclerosis (MS) market. Three years later, ...

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (ABOS) (NASDAQ: ABOS) (“Acumen” or the “Company ...

Shortly after acquiring Elektrofi to beef up its subcutaneous drug-delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio. To take over Surf, Halozyme is paying $300 ...

MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple myeloma patients. The IRAKLIA study enrolled 532 patients globally, ...

A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...

Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...